George Mason University and TGen announce alliance
- May 6, 2014
Fairfax-based George Mason University announced Monday it has formed a precision medicine alliance to help patients with cancer and other life-threatening illnesses.
The public university has created the TGen-George Mason Molecular Medicine Alliance with the Translational Genomics Research Institute (TGen), a nonprofit research organization in Phoenix that focuses on helping patients with cancer, neurological disorders and diabetes. The alliance recommends to doctors the medications and treatments based on each patient's molecular profile.
The alliance will initially focus on:
• New treatments for patients with breast cancer or melanoma.
• Treatments for patients with breast cancer that has spread to the bone and brain.
• Biomarkers that can help diagnose traumatic injuries, such as brain concussions.
• Developing a better understanding of infectious diseases and the human immune system, leading to new vaccines.
The alliance has already submitted applications for more than $12 million in research grants, TGen said in a news release.